Nordic Nanovector ASA (NRNVF) Stock Price, News & Analysis

Company Overview

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway and internationally. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. Nordic Nanovector ASA has collaboration agreements with Paul Scherrer Institute; Areva Med; LegoChem Bio; and Heidelberg Pharma. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.

Key Stats

• Today's Range: $1.64 to $1.64
• 50-Day Range: $1.64 to $1.64
• 52-Week Range: $1.64 to $1.64
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NRNVF Stock Analysis - Frequently Asked Questions

How have NRNVF shares performed this year?

Nordic Nanovector ASA's stock was trading at $1.6383 on January 1st, 2025. Since then, NRNVF stock has increased by 0.0% and is now trading at $1.6383.
View the best growth stocks for 2025 here.

How do I buy shares of Nordic Nanovector ASA?

Shares of NRNVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:NRNVF
• CIK: N/A
• Web: www.nordicnanovector.com
• Phone: 47 22 18 33 01
• Fax: N/A
• Employees: 39
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A